📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: Lipocine

1.1 - Company Overview

Lipocine Logo

Lipocine

Headquarter: United States
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of specialty pharmaceutical products, including TLANDO, an FDA-approved oral testosterone replacement therapy; LPCN 1111, an oral testosterone prodrug for hypogonadal men; LPCN 1144 and 1148, oral prodrugs of bioidentical testosterone for NASH and cirrhosis symptoms; LPCN 1107, an oral candidate to prevent recurrent preterm birth (FDA orphan drug); and LPCN 1154, an oral neurosteroid for postpartum depression.

Products and services

  • TLANDO: Delivers FDA-approved oral testosterone replacement therapy (TRT), offering an oral option for therapeutic testosterone replacement
  • LPCN 1111: Delivers a next-generation oral prodrug of testosterone enabling once-daily dosing in hypogonadal men, designed to achieve daily oral testosterone therapy
  • LPCN 1144: Offers an oral prodrug of bioidentical testosterone for treating non-alcoholic steatohepatitis (NASH), providing a hormone-derived therapeutic approach via oral administration

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to Lipocine

Lypro Bio Logo

Lypro Bio

HQ: United States Website
  • Description: Provider of NanoDisk drug delivery technology to increase solubility and bioavailability of hydrophobic drugs, with applications in cancer (curcumin and all-trans retinoic acid for glioblastoma multiforme and mantle cell lymphoma), infectious diseases (amphotericin B for Leishmania major and Aspergillosis), and neurodegenerative disease research; also offers Ambigent, an antifungal reagent for high-value cell cultures.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Lypro Bio company profile →
PharmaJet Logo

PharmaJet

HQ: United States Website
  • Description: Provider of needle-free jet injection systems for fixed-dose intradermal, intramuscular, and subcutaneous vaccine delivery. Offerings include Tropis ID (0.1 ml intradermal), Stratis IM/SC (0.5 ml IM/SC with charging station), and platforms for nucleic acid, COVID-19 (e.g., ZyCoV-D), polio, and influenza (e.g., Afluria) vaccine delivery, enhancing cellular dispersion and immunogenicity and providing an alternative to needles.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full PharmaJet company profile →
Renovis Logo

Renovis

HQ: United States Website
  • Description: Provider of biopharmaceutical drug development for neurological diseases and disorders, currently developing products for acute ischemic stroke, neuropathic pain, and acute post-operative pain.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Renovis company profile →
ActivaTek Logo

ActivaTek

HQ: United States Website
  • Description: Provider of drug delivery and other medical devices, including iontophoretic products for the rehabilitation market. Manufacturer of ActivaDose dose controllers; ActivaDose II houses a 9-volt battery and features precise dosing, visual and audible displays, and dual channels.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full ActivaTek company profile →
Cellectar Biosciences Logo

Cellectar Biosciences

HQ: United States Website
  • Description: Provider of radiopharmaceutical cancer therapies and diagnostics, designing phospholipid drug conjugates that target tumor cells to detect, treat, and monitor cancers. Lead candidate iopofosine I 131 is in Phase 2/1 studies. Pipeline includes CLR 1900 cytotoxic compounds and collaborative PDC programs (CLR 2000, CLR 12120) with Avicenna and Orano Med, plus new PDCs with IntoCell and LegoChemBio.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Cellectar Biosciences company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for Lipocine

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Lipocine

2.2 - Growth funds investing in similar companies to Lipocine

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Lipocine

4.2 - Public trading comparable groups for Lipocine

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Lipocine

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Lipocine

What does Lipocine do?

Lipocine is a provider of specialty pharmaceutical products, including TLANDO, an FDA-approved oral testosterone replacement therapy; LPCN 1111, an oral testosterone prodrug for hypogonadal men; LPCN 1144 and 1148, oral prodrugs of bioidentical testosterone for NASH and cirrhosis symptoms; LPCN 1107, an oral candidate to prevent recurrent preterm birth (FDA orphan drug); and LPCN 1154, an oral neurosteroid for postpartum depression.

Who are Lipocine's competitors?

Lipocine's competitors and similar companies include Lypro Bio, PharmaJet, Renovis, ActivaTek, and Cellectar Biosciences.

Where is Lipocine headquartered?

Lipocine is headquartered in United States.

How many employees does Lipocine have?

Lipocine has 1,000 employees 🔒.

When was Lipocine founded?

Lipocine was founded in 2010 🔒.

What sector and industry vertical is Lipocine in?

Lipocine is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Lipocine

Who are the top strategic acquirers in Lipocine's sector and industry

Top strategic M&A buyers and acquirers in Lipocine's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Lipocine?

Top strategic M&A buyers groups and sectors for Lipocine include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Lipocine's sector and industry vertical

Which are the top PE firms investing in Lipocine's sector and industry vertical?

Top PE firms investing in Lipocine's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Lipocine's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Lipocine's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Lipocine's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Lipocine include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Lipocine's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Lipocine?

The key public trading comparables and valuation benchmarks for Lipocine include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Lipocine for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Lipocine with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Lipocine's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Lipocine with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Lipocine's' sector and industry vertical?

Access recent funding rounds and capital raises in Lipocine's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Lipocine